NCT02468375

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

A Multicenter Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 434 (actual)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to measure the treatment satisfaction after switching to mirabegron in patient with Overactive Bladder(OAB) who were unsatisfied with efficacy of antimuscarinic therapy or adverse event. Patient will take the mirabegron 50mg/day for 12 weeks, and the satisfation of the therapy will be measured with Treatment Satisfaction Questionnaire(TSQ), Global Response Assessment(GRA), OAB-q short form, OAB Symptom Score and Willingness to continue Questions.

Conditions

• Overactive Bladder

Interventions

Type	Name	Description
DRUG	mirabegron 50mg	434 OAB patient intake mirabegron 50mg/day for 12 weeks.

Timeline

• Start date: 2015-06-01
• Primary completion: 2017-10-01
• Completion: 2017-12-01
• First posted: 2015-06-10
• Last updated: 2018-02-28

Locations

1 site across 1 country: South Korea